Sepsis News and Research

Latest Sepsis News and Research

Gene manipulation can improve survival rates during sepsis infection

Sepsis is a major killer in hospital intensive care units. Researchers at Case Western Reserve University School of Medicine have found that manipulating a genetic factor that can launch or throttle the body's defenses can improve survival rates during bacterial infection.

13 May 2011

Atox Bio completes AB103 phase 1 study in severe bacterial infections and sepsis

Atox Bio Inc. today announced that it successfully completed a phase 1 clinical study of AB103, a novel therapy for the treatment of severe bacterial infections and sepsis.

12 May 2011

ImmunID, Centre Léon Bérard and Cytheris commence CYT107-XELODA Phase IIa trial in metastatic breast cancer

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, the Centre Léon Bérard, the major cancer research and treatment center for the Rhône-Alpes region of France, and ImmunID Technologies SAS, a diagnostic company specialized in innovative immunomonitoring tests and services, today announced initiation of a Phase IIa clinical trial that will evaluate multiple combinations of recombinant human interleukin-7, the investigational multifunctional cytokine under development by Cytheris, and a chemotherapeutic agent, XELODA, in the treatment of metastatic breast cancer.

11 May 2011

Journal of Rheumatology publishes positive results from Cimzia Phase III trial in RA

UCB announced today results from a post hoc analysis of the RAPID 1 study published in the Journal of Rheumatology. The results suggest moderate to severe rheumatoid arthritis patients treated with Cimzia, the only approved PEGylated anti-TNF, together with methotrexate, achieved a rapid response associated with improved long-term outcomes one year after treatment began.

11 May 2011

Allos, Mundipharma enter strategic collaboration to co-develop FOLOTYN

Allos Therapeutics, Inc. and Mundipharma International Corporation Limited today jointly announced that the companies have entered into a strategic collaboration agreement to co-develop FOLOTYN (pralatrexate injection).

11 May 2011

Peripheral venous catheters cause over 10% of catheter-related bloodstream infections

A new study from Rhode Island Hospital has found that more than one in 10 catheter-related bloodstream infections due to Staph aureus in hospitalized adults are caused by infected peripheral venous catheters (PVC). The study points out the substantial medical burden that arises from complications from these infections due to the large number of such catheters used in hospitalized patients.

4 May 2011

Statins can help reduce lung damage in severe abdominal sepsis

Statins may be best known for their ability to reduce cholesterol, but a research report appearing in the May 2011 issue of the Journal of Leukocyte Biology shows that these same drugs could also play a crucial role in the reduction of lung damage resulting from severe abdominal sepsis and infection.

3 May 2011

AACN to honor 22 nurses nationwide with 2011 Circle of Excellence Award

The American Association of Critical-Care Nurses will bestow the 2011 Circle of Excellence Award on 22 nurses nationwide at the National Teaching Institute & Critical Care Exposition, Chicago, April 30-May 5.

30 Apr 2011

Low-cost colorimetric sensing array identifies bacterial infections

Bacterial infections really stink. And that could be the key to a fast diagnosis.

28 Apr 2011

Promising pain medication may decrease ability to fight off sepsis

Pain researchers from the Sheikh Zayed Institute for Pediatric Surgical Innovation at Children's National Medical Center have discovered that resiniferatoxin, a drug that has shown early promise as an option for chronic, severe pain sufferers, may decrease the body's ability to fight off bacterial infections, particularly sepsis.

27 Apr 2011

Rwanda, QIAGEN and Merck launch comprehensive national cervical cancer prevention program

The Government of Rwanda, together with QIAGEN N.V. and Merck, known as MSD outside the United States and Canada, today announced the launch, in Kigali, Rwanda, of a comprehensive national cervical cancer prevention program that includes vaccination with GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for appropriate girls 12 to 15 years of age and modern molecular diagnostic screening for women between the ages of 35 and 45.

From QIAGEN Manchester Limited 25 Apr 2011

Group B streptococci continues to increase risk of sepsis in newborns

Bloodstream infections in newborns can lead to serious complications with substantial morbidity and mortality. What's more, the pathogens responsible for neonatal infections have changed over time. In recent years, however, antibiotic prophylaxis given to at-risk mothers has reduced the incidence of early-onset group B streptococcal infections among their babies.

25 Apr 2011

Sanofi Pasteur receives FDA approval for Menactra to prevent meningococcal disease

The U.S. Food and Drug Administration today approved the use of Menactra in children as young as 9 months for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135. Menactra already is approved for use in people ages 2 through 55 years.

24 Apr 2011

CTIS Pregnancy Health Information Line aims to educate women about meningitis

The California Teratogen Information Service Pregnancy Health Information Line, a state-wide non-profit organization based at the University of California, San Diego with affiliates across North America, will join in the effort to raise awareness of meningitis prevention by helping to launch a new study that will assess safety of the meningitis vaccine in pregnancy.

22 Apr 2011

Drug resistant bug plaguing the meat industry: Study

It has been found that nearly half of the meat and poultry (47 percent) sold in U.S. grocery stores is contaminated with Staphylococcus aureus (“Staph”), a bacteria linked to a wide range of human diseases, and this bacteria is resistant to at least three classes of antibiotics in more than half (52 percent) of contaminated samples. This comes from a nationwide study by the Translational Genomics Research Institute (TGen) published this week in the journal Clinical Infectious Diseases.

17 Apr 2011

Hospital patients with AUDs are at increased risk of developing HAIs: Study

Hospital patients with alcohol use disorders are at an increased risk of developing healthcare-associated infections, which affect 1.7 million patients annually in the United States. HAIs are infections that patients acquire during their hospitalization and that were not present at the time of admission to the hospital.

16 Apr 2011

Study finds 47% of meat and poultry samples contaminated with S. aureus

Drug-resistant strains of Staphylococcus aureus, a bacteria linked to a wide range of human diseases, are present in meat and poultry from U.S. grocery stores at unexpectedly high rates, according to a nationwide study by the Translational Genomics Research Institute.

15 Apr 2011

Study shows neutralizing antibodies to C5a protein may prevent heart failure

New research published online in The FASEB Journal details research in rats and mice that offers hope for stopping the devastating, and often fatal, effects of sepsis in humans. In the study, University of Michigan researchers show how neutralizing the effects of a key protein fragment, called C5a, used by the immune system to attract white blood cells may ultimately prevent heart failure.

12 Apr 2011

Viral infection likely to encourage pneumonia spread

Bacteria that cause pneumonia and meningitis are only able to spread when individuals are infected with flu, says a scientist reporting at the Society for General Microbiology's Spring Conference in Harrogate. The work could have implications for the management of influenza pandemics and could help reduce incidence of pneumococcal infections in very young children, who are more susceptible to disease.

11 Apr 2011

Positive data from PROCHIEVE vaginal progesterone Phase III study published in peer-reviewed journal

Columbia Laboratories, Inc., and Watson Pharmaceuticals, Inc., today announced the publication of Phase III PROCHIEVE® (progesterone gel) data in today's online version of Ultrasound in Obstetrics & Gynecology, the leading peer-reviewed journal of the International Society of Ultrasound in Obstetrics & Gynecology.

7 Apr 2011